Product image of Nolpaza (Pantoprazole) supplied by GNH India

Nolpaza

Active Ingredient:
Pantoprazole
Origin:
EU

Nolpaza (Pantoprazole)

Pantoprazole, the active ingredient in Nolpaza, is a proton pump inhibitor presented as an injection solution for intravenous use. It reduces gastric acid secretion and is employed in the management of acid‑related disorders such as gastro‑oesophageal reflux disease, erosive esophagitis, Zollinger‑Ellison syndrome, and in the prevention of NSAID‑induced gastric ulcers in hospitalized patients.

GNH India supplies Nolpaza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is distributed across European and global markets.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nolpaza (pantoprazole) is used to treat acid‑related disorders by suppressing gastric acid production.

  • Gastro‑oesophageal reflux disease (GERD): reduces acid exposure and promotes healing of esophageal mucosa.
  • Erosive esophagitis: facilitates ulcer resolution and symptom relief.
  • Zollinger‑Ellison syndrome: controls hypersecretion of gastric acid.
  • Prevention of NSAID‑induced gastric ulcers: lowers risk of ulcer formation in patients receiving NSAIDs.

How It Works

  • Pantoprazole selectively and irreversibly inhibits the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By blocking this final step of acid secretion, it markedly reduces both basal and stimulated gastric acid output, leading to an increased gastric pH. The inhibition persists until new proton pumps are synthesized, providing prolonged acid suppression after a single intravenous dose.

Side Effects

Adverse reactions to Nolpaza may vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate pain in the head.
  • Nausea: feeling of queasiness.
  • Diarrhea: loose stools.
  • Abdominal pain: discomfort in the stomach area.
  • Injection site reaction: redness or swelling at the infusion site.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction with airway compromise.
  • Clostridioides difficile infection: severe colitis associated with antibiotic use.
  • Hepatotoxicity: significant elevation of liver enzymes.
  • Thrombocytopenia: marked reduction in platelet count.
  • Stevens‑Johnson syndrome: rare severe skin reaction.

Precautions & Warnings

When using Nolpaza, clinicians should observe several precautionary measures to ensure patient safety.

  • Assess renal function: adjust use in severe renal impairment.
  • Monitor electrolytes: watch for hypomagnesemia and related disturbances.
  • Evaluate for infection: increased risk of Clostridioides difficile colitis.
  • Use cautiously in hepatic impairment: monitor liver function tests.
  • Avoid in known hypersensitivity: discontinue if allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Nolpaza can affect the pharmacokinetics of several medicines; interactions should be reviewed before co‑administration.

Major Interactions (Avoid)

  • Rilpivirine: reduced absorption and antiviral efficacy.
  • Atazanavir: decreased plasma concentrations, risking treatment failure.
  • Methotrexate: increased toxicity due to reduced renal clearance.
  • Clopidogrel: diminished activation, potentially reducing antiplatelet effect.

Moderate Interactions (Monitor Closely)

  • Warfarin: possible alteration of INR, monitor coagulation.
  • Digoxin: potential increase in serum levels, observe for toxicity.
  • Ketoconazole: decreased absorption, may require dose adjustment.

Frequently Asked Questions

Nolpaza is an intravenous formulation of pantoprazole indicated for the treatment of acid‑related conditions such as gastro‑oesophageal reflux disease, erosive esophagitis, Zollinger‑Ellison syndrome, and for the prevention of gastric ulcers in patients receiving non‑steroidal anti‑inflammatory drugs.

Pantoprazole belongs to the proton pump inhibitor class. It binds irreversibly to the H+/K+ ATPase enzyme (the gastric proton pump) on parietal cells, blocking the final step of acid secretion and thereby raising gastric pH and reducing both basal and stimulated acid output.

The prescribed dose of Nolpaza is determined by the treating physician based on the specific indication, patient condition, and clinical response. Dosing may vary for different disorders and is adjusted according to renal or hepatic function when necessary.

Safety data for pantoprazole in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the prescriber in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Nolpaza (pantoprazole) offers a stable intravenous formulation with a low potential for drug‑drug interactions compared with some other PPIs such as omeprazole. Its pharmacokinetic profile provides consistent acid suppression, making it suitable for rapid inpatient management of severe acid‑related conditions.

Nolpaza must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside the recommended range.

Nolpaza is administered by intravenous infusion. The solution is diluted in an appropriate compatible fluid and infused over the period recommended by the prescribing information, typically ranging from a few minutes to an hour, depending on the clinical situation.

Serious adverse events include anaphylactic reactions, severe Clostridioides difficile‑associated colitis, significant liver enzyme elevations, thrombocytopenia, and rare skin disorders such as Stevens‑Johnson syndrome. Patients should be monitored for signs of hypersensitivity, gastrointestinal infection, and hepatic dysfunction.

Nolpaza is contraindicated in patients with a known hypersensitivity to pantoprazole or any component of the formulation. Caution is also advised for individuals with severe renal or hepatic impairment, and it should be avoided in patients who have experienced severe allergic reactions to other proton pump inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Pantoprazole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT